{"created":"2023-05-18T10:11:18.041836+00:00","id":3035,"links":{},"metadata":{"_buckets":{"deposit":"8fd340fd-f5ea-4ac4-acba-7b9022b07eca"},"_deposit":{"created_by":5,"id":"3035","owners":[5],"pid":{"revision_id":0,"type":"depid","value":"3035"},"status":"published"},"_oai":{"id":"oai:yamanashi.repo.nii.ac.jp:00003035","sets":["205:251:269"]},"author_link":["13979","13980","13981","13982","13983","13984"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1998","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"97","bibliographicPageStart":"89","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"山梨医科大学雑誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Yamanashi medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_creator_2":{"attribute_name":"著者名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"飯塚, 秀彦","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"山本, 正之","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"松本, 由朗","creatorNameLang":"ja"}],"nameIdentifiers":[{}]}]},"item_10001_description_5":{"attribute_name":"内容","attribute_value_mlt":[{"subitem_description":"進行肝細胞癌患者の新しい治療法の確立をめざし,lymphokine activated kiiier cells (LAK)療法ならびにinterleukin-2 (IL-2)の持続肝動脈内注入療法(持続肝動注療法)の有用性を検討した。I. LAK療法:3例の男性の肝細胞癌患者を対象とし,肝動脈内留置カテーテルから,LAK細胞を,それぞれ1.0×10^8,2.8×10^8,3.5×10^8個投与し,さらに8時間毎にIL-2 3.8×10^5JRUを3回投与した。しかし,全例が腫瘍の進行(PD)を示し,肝硬変を合併した進行肝細胞癌患者に対するLAK療法には限界があると考えられた。II. Adriamycin-Lipiodol emulsion(ADR-Lip)の間歇投与を併用したIL-2持続肝動脈内注入療法:進行肝細胞癌患者24例を対象とし,IL-2(S-6820,塩野義製薬,大阪)の持続肝動注療法とADR-Lipの間歇的投与を17例(A群)に,ADR-Lipの間歇投与のみを7例(B群)に施行した。抗腫瘍効果はA群で著効(CR)4例,有効(PR)2例で奏功率は35.3%,B群ではPR 2例で奏功率は28.6%であり,奏功率,CR率ともに有意差はなかった。また,両群の累積生存率に有意差を認めなかった。一方,末梢血NK活性は治療開始 4-5か月後にはA群で53.1±13.8%と増強し,B群に比べて有意に高値となり,この時期に抗腫瘍効果を得た。しかし,8-9か月後には低下し,有意差は認められなくなった。同様に,A群においては末梢血IL-2 receptor陽性細胞の割合および末梢血LAK活性は 4-5か月後には増強し,8-9か月後には低下した。進行肝細胞癌患者に対する補助免疫療法における奏功率,累積生存率の改善には,末梢血NK活性,末梢血IL-2 receptor陽性細胞の割合,末梢血LAK活性を長期にわたり高値に保つ治療法の開発が必要である。","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10001_full_name_24":{"attribute_name":"著者名(別表記)","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"13982","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Iizuka, Hidehiko","nameLang":"en"}]},{"nameIdentifiers":[{"nameIdentifier":"13983","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Yamamoto, Masayuki","nameLang":"en"}]},{"nameIdentifiers":[{"nameIdentifier":"13984","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Matsumoto, Yoshirou","nameLang":"en"}]}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.34429/00003028","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"山梨医科大学医学会","subitem_publisher_language":"ja"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10044054","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0912-0025","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_4":{"attribute_name":"タイトルヨミ","attribute_value_mlt":[{"subitem_text_language":"ja-Kana","subitem_text_value":"ゲンチョ カン サイボウガン ニ タイスル アタラシイ チリョウ センリャク ノ カイハツ ニ カンスル ケンキュウ タンガン カンジャ ノ メンエキ ヨクセイ ジョウタイ ノ カイゼン オ メザシタ メンエキガクテキ チリョウ"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-27"}],"displaytype":"detail","filename":"AN10044054_13_03_03.pdf","filesize":[{"value":"961.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"AN10044054_13_03_03.pdf","objectType":"fulltext","url":"https://yamanashi.repo.nii.ac.jp/record/3035/files/AN10044054_13_03_03.pdf"},"version_id":"f78d156b-546b-40d7-9be2-da8ceeeb6b08"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"進行肝細胞癌","subitem_subject_language":"ja"},{"subitem_subject":"インターロイキン2","subitem_subject_language":"ja"},{"subitem_subject":"養子免疫療法","subitem_subject_language":"ja"},{"subitem_subject":"NK活性","subitem_subject_language":"ja"},{"subitem_subject":"動注免疫化学療法","subitem_subject_language":"ja"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"<原著>肝細胞癌に対する新しい治療戦略の開発に関する研究-担癌患者の免疫抑制状態の改善をめざした免疫学的治療-","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"<原著>肝細胞癌に対する新しい治療戦略の開発に関する研究-担癌患者の免疫抑制状態の改善をめざした免疫学的治療-","subitem_title_language":"ja"}]},"item_type_id":"10001","owner":"5","path":["269"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2010-05-18"},"publish_date":"2010-05-18","publish_status":"0","recid":"3035","relation_version_is_last":true,"title":["<原著>肝細胞癌に対する新しい治療戦略の開発に関する研究-担癌患者の免疫抑制状態の改善をめざした免疫学的治療-"],"weko_creator_id":"5","weko_shared_id":-1},"updated":"2023-10-11T07:33:51.118408+00:00"}